[Bone remodeling: new therapeutic approaches].
High bone remodeling leads to bone loss and microarchitectural deteriorations characteristic of osteoporosis. Bisphosphonates and selective estrogen receptor modulators decrease bone remodeling by preventing osteoclast-mediated bone resorption, whereas parathyroid hormone/teriparatide increase bone remodeling in favor of new bone formation. Better understanding of the molecular processes of bone remodeling has led to the development of agents to inhibit bone resorption, such as the human monoclonal antibody Denosumab targeting osteoclast-activating factor RANK Ligand, and odanacatib targeting the collagen-degrading enzyme cathepsin K. Agents capable to stimulate bone formation independently of bone resorption, such as antagonists of the osteoblast-inhibitory factor sclerostin, may provide new therapeutic approaches to osteoporosis.